Sphingolipids in Cancer

Erscheinungsjahr 2018
ISBN: 978-0-12-814223-3
Verlag: William Andrew Publishing

Buch, Englisch, 410 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 880 g

Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

Zielgruppe

<p>Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.</p>

Autoren/Hrsg.

Weitere Mitwirkende

Chalfant, Charles E.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. Mechanisms of ceramide-dependent cancer cell deathRose Nganga, Natalia Oleinik and Besim Ogretmen 2. Sphingolipids as regulators of autophagy and endocytic traffickingMegan M. Young and Hong-Gang Wang3. Role and function of sphingomyelin biosynthesis in the development of cancerGiovanni D'Angelo, Sitapriya Moorthi and Chiara Luberto4. Neutral sphingomyelinases in cancer: friend or foe?Christopher J. Clarke5. Ceramide and exosomes: a novel target in cancer biology and therapyAhmed Elsherbini and Erhard Bieberich6. Sphingolipids at the crossroads of NAFLD and senescenceMariana Nikolova-Karakashian7. Ceramide signaling and p53 pathwaysKristen Jeffries and Natalia Krupenko8. The role of ceramide 1-phosphate in tumor cell survival and disseminationAntonio Gomez-Muñoz9. The onus of sphingolipid enzymes in cancer drug resistanceSamy A.F. Morad and Myles C. Cabot10. Interdiction of sphingolipid metabolism revisited: focus on prostate cancerChristina Voelkel-Johnson, James S. Norris and Shai White-Gilbertson11. Targeting sphingosine kinases for the treatment of cancerClayton S. Lewis, Christina Voelkel-Johnson and Charles D. Smith12. Novel sphingolipid-based cancer therapeutics in the personalized medicine eraJeremy Shaw, Pedro Costa-Pinheiro, Logan Patterson, Kelly Drews, Sarah Spiegel and Mark Kester13. Side effects in cancer therapy: are sphingolipids to blame?Falak Patel and Stefka D. Spassieva

Über Autor(innen)

Chalfant, Charles E.
Professor Charles E. Chalfant heads up the Chalfant Laboratory and is the director of the Lipidomic Facility at Virgina Commonwealth University. The Chalfant laboratory is currently focused on two major areas of cell signaling and human pathophysiologies: 1) lipid and oncogenic regulation of alternative splicing; and 2) the regulation of eicosanoid synthesis in inflammation and cancer.